Business
BioElectronics and Pulsed Shortwave Therapy Make Progress
BioElectronics and Pulsed Shortwave Therapy Make Progress.
About this update from Bioelectronics Corp.
[{"type":"text","content":"\n\n\n\n\n\n\n\nBioElectronics and Pulsed Shortwave Therapy Make Progress\n\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:\"0in\";\n}\n\n\n\n\n\n\n\n\n\n\nBioElectronics and Pulsed Shortwave Therapy Make Progress\n\nPublic Advisory Panel Accepts FDA's Class II Re-Classification Suggestion\n\nPR Newswire\n\nFREDERICK, Md., May 23, 2013\n\n\n\n\n\n\n\nFREDERICK, Md., May 23, 2013 /PRNewswire/ -- BioElectronics Corporation (OTC Pink: BIEL), the maker of very effective, safe consumer medical devices, comments on the FDA panel meeting for non-thermal shortwave diathermy:\n\n\nThe FDA's Public Advisory Panel Reclassification – Pulsed Shortwave Therapy Meeting was held on May 21, 2013 in Gaithersburg, MD, USA. The focus of the meeting was very narrow, in that the FDA had instructed the panel to focus solely on the application of non-thermal shortwave diathermy for the treatment of postoperative pain and edema and the treatment of edema following blepharoplasty. Industry representatives, including BioElectronics President Andy Whelan, presented a compelling case for reclassification. The recommendation from the FDA's advisory panel was reclassification from Class III to Class II with special controls including a requirement for new clinical data. At this time it is not clear if the requirement for new clinical data applies to existing products. The FDA will make a final decision on the recommendations of the panel in due course, though BioElectronics believes that the FDA will follow the panel's recommendations.\n\n\n\"Overall, we see the advisory panel and the FDA's recommendations as a positive and potentially significant development,\" stated Ian Rawe, BioElectronics Director of Clinical Research. \"After decades of use and research, the FDA now believes that the available evidence suggests that shortwave devices can be safely regulated. If existing cleared devices are compelled to submit new clinical data, our 3rd Molar Extraction clinical study at Tufts Dental School, Boston, meets all the FDA's clinical research standards. This study is evaluating bot...